13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • BEACON

    Acronym: 

    BEACON

    ACTRN/NCT /ethics: 

    Scientific title: 

    Summary of trial and patient characteristics

    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III Tumour Stream Bowel and Colon
    Age Range 18 years and older Cancer Stage Metastatic or Widespread
    Sex Both Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Bowel and colon
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Bowel and Colon
    Cancer Stage Metastatic or Widespread
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A multicenter, randomized, open-label, 3-arm phase III study of the encorafenib + cetuximab plus or minus binimetinib vs. irinotecan/cetuximab or infusional 5- fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan, Trifluridine/Tipiracil in RAS wild-type patients with metastatic colorectal cancer

    Lay Summary

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    The Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 Tim Price Recruiting